These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 20083002)
1. Did levodopa vs. dopamine agonist trials teach us when and how to start symptomatic therapy? Waters C Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S31-3. PubMed ID: 20083002 [No Abstract] [Full Text] [Related]
2. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
4. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?]. Defer GL Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847 [No Abstract] [Full Text] [Related]
5. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738 [No Abstract] [Full Text] [Related]
7. When and how should treatment be started in Parkinson disease? Lang AE Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313 [TBL] [Abstract][Full Text] [Related]
8. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
9. The variability of levodopa response in Parkinson's disease: is sensitization reversible? Jabre MG; Bejjani BP Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452 [No Abstract] [Full Text] [Related]
10. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
12. Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ; Torjanski N; Burn DJ J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630 [TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176 [No Abstract] [Full Text] [Related]
14. Clinical inquiries. What is the best initial treatment of Parkinson's disease? Schreck J; Kelsberg G; Rich J; Ward R J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387 [No Abstract] [Full Text] [Related]
15. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review]. Bode M Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2003 Dec; (10):1582-98. PubMed ID: 15555162 [No Abstract] [Full Text] [Related]